| abstract |
The present disclosure relates to a pharmaceutical product comprising (i) a MET inhibitor that is INC280, or a pharmaceutically acceptable salt or hydrate thereof, and (ii) an EGFR inhibitor that is a monoclonal antibody, such as cetuximab or Nitumab, they work together in the treatment of proliferative diseases, and corresponding pharmaceutical preparations, applications, methods, processes, commercial packages and related embodiments. |